Key result
Discontinuing OAC after successful AF ablation reduces major bleeding without increasing thromboembolic events.
Why the study?
The decision to continue or discontinue OAC after catheter ablation requires balancing thromboembolic and bleeding risks, and the need for long-term OAC after successful AF ablation remains unclear.
Does discontinuing oral anticoagulation reduce major bleeding without increasing thromboembolic events in patients following successful atrial fibrillation ablation?
Meta-Analysis (n=249,452)
Does discontinuing oral anticoagulation reduce major bleeding without increasing thromboembolic events in patients following successful atrial fibrillation ablation?
Relative Risk: 0.932 (95% CI 0.624–1.393)
Discontinuing oral anticoagulation after successful AF ablation may significantly reduce major bleeding without increasing the risk of thromboembolism, though current evidence quality is low.
Supports OAC discontinuation after successful AF ablation to lower bleeding risk; challenges guideline-directed continuation based on CHA₂DS₂-VASc alone.
Background The decision to continue or discontinue oral anticoagulation (OAC) after catheter ablation for atrial fibrillation (AF) requires balancing thromboembolic and bleeding risks, and the need for long-term OAC after a successful procedure remains unclear. Thus, we aim to evaluate the safety of discontinuing OAC compared with continuation after apparently successful AF ablation. Methods PubMed, Embase, Cochrane Central, and Web of Science were searched for randomized controlled trial and cohort studies comparing OAC discontinuation with continuation. Eligible studies required no evidence of AF recurrence before group allocation. A random-effects model with Hartung-Knapp-Sidik-Jonkman adjustment was used to estimate pooled risk ratios (RR) and hazard ratios (HR) with 95% confidence intervals (CI). Results Thirteen studies encompassing 249,452 patients were included. No difference was observed between groups for thromboembolic events (RR 0.932; 95% CI 0.624 to 1.393; GRADE: very low quality of evidence), nor when stratifying for patients with CHA2DS2-VASc ≥ 2 (RR 1.289; 95% CI 0.673 to 2.469) or < 2 (RR 0.786; 95% CI 0.353 to 1.751). For major bleeding, discontinuing OAC was associated with a significant reduction in events (RR 0.332; 95% CI 0.167 to 0.659; GRADE: low quality of evidence). Finally, for all-cause mortality, no difference between groups was observed (HR 0.977; 95% CI 0.889 to 1.073; GRADE: very low quality of evidence). Conclusion Discontinuing OAC after successful AF ablation may reduce the risk of major bleeding while not increasing the risk of thromboembolism. However, further studies with proper designs are needed to confirm these associations.
No takes yet. Share an insight, caveat, or question.
Lôbo et al. (2026) conducted a meta-analysis in Atrial fibrillation (n=249,452). Discontinuation of oral anticoagulation vs. Continuation of oral anticoagulation was evaluated on Thromboembolic events (RR 0.932, 95% CI 0.624 to 1.393). Discontinuing oral anticoagulation after successful atrial fibrillation ablation did not increase thromboembolic events (RR 0.932; 95% CI 0.624-1.393) and significantly reduced major bleeding.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: